Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds (AEGIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04240886
Recruitment Status : Recruiting
First Posted : January 27, 2020
Last Update Posted : April 24, 2020
Sponsor:
Information provided by (Responsible Party):
Amplyx Pharmaceuticals

Brief Summary:
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).

Condition or disease Intervention/treatment Phase
Invasive Fungal Infections Drug: fosmanogepix Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds
Actual Study Start Date : January 4, 2020
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : October 2021

Arm Intervention/treatment
Experimental: fosmanogepix (APX001) Drug: fosmanogepix
IV and oral fosmanogepix
Other Names:
  • APX001
  • E210




Primary Outcome Measures :
  1. All-Cause Mortality [ Time Frame: Day 42 ]

Secondary Outcome Measures :
  1. Global Response [ Time Frame: End of Study Treatment or Day 42 ]

Other Outcome Measures:
  1. All-Cause Mortality [ Time Frame: Day 84 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females, 18 years or older.
  • Patients with proven or probable IMI caused by Aspergillus spp. Patients who present with IMI due to other filamentous fungi (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi such as Mucor spp. or Rhizopus spp.) may also be enrolled.
  • Have limited or no treatment options due to documented or anticipated resistance, contraindication, intolerance, or lack of clinical response to SOC antifungal therapy, as advocated by the relevant regional/country treatment guidelines.
  • Patients where the Investigator considers that there is a potential advantage of using APX001 over current SOC (eg, broad spectrum of activity, emergence of IMI during antifungal prophylaxis, activity against resistant mold pathogens, IV and PO formulations, favorable DDI profile, favorable hepatic and renal safety profile, wide tissue distribution including brain), and/or where the SOC antifungal therapy carries significant risk of toxicity or treatment failure (eg, DDI risk, safety/toxicity risk, site of infection not accessible by SOC).

Exclusion Criteria:

  • Refractory hematologic malignancy.
  • Chronic aspergillosis, aspergilloma, or allergic bronchopulmonary aspergillosis.
  • Treatment with systemic (PO, IV, or inhaled) mold active antifungal therapy for 120 hours immediately before initial dosing. Note: patients with invasive fungal infection caused by a mold with documented resistance to or lack of coverage by the prior SOC in question, may have received >120 hours prior treatment and remain eligible for the study.
  • Evidence of significant hepatic dysfunction.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04240886


Contacts
Layout table for location contacts
Contact: Susan Hazel +1.858.436.7204 shazel@amplyx.com

Locations
Layout table for location information
Belgium
Clinical Trial Site Recruiting
Brussels, Belgium, 1000
Clinical Trial Site Recruiting
Brussels, Belgium, 1070
Clinical Trial Site Recruiting
Leuven, Belgium, 3000
Clinical Trial Site Recruiting
Yvoir, Belgium, 5530
Germany
Clinical Trial Site Recruiting
Mainz, Germany
Israel
Clinical Trial Site Recruiting
Haifa, Israel
Clinical Trial Site Recruiting
Tel Aviv, Israel
Clinical Trial Site Recruiting
Tel HaShomer, Israel
Sponsors and Collaborators
Amplyx Pharmaceuticals
Layout table for additonal information
Responsible Party: Amplyx Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04240886    
Other Study ID Numbers: APX001-202
2019-001386-33 ( EudraCT Number )
First Posted: January 27, 2020    Key Record Dates
Last Update Posted: April 24, 2020
Last Verified: April 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Amplyx Pharmaceuticals:
APX001
APX001A
fosmanogepix
manogepix
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Mycoses
Invasive Fungal Infections